(Bloomberg) -- Members of Congress are in an unusual position asthey demand an explanation for Mylan NV’s 400 percentprice hike for the EpiPen and focusattention squarely on its CEO: Heather Bresch.

|

Related: Senators blast pharma executives for pricehikes

|

If lawmakers follow the usual script, Bresch could getcalled up to Capitol Hill next month to explain her company’sjustification for raising the price on the life-saving allergyshot. But that could be awkward, since she’s the daughter ofDemocratic Senator Joe Manchin of West Virginia.

|

The scrutiny on EpiPen intensified Wednesday after Democraticnominee Hillary Clinton called the price increase “outrageous,”sending Mylan’s stock down as much as 6.2 percent.

|

The intense political pressure could lead regulators to speed uptheir review of a rival product by Teva Pharmaceutical IndustriesLtd., according to some analysts, or force Mylan to curb prices --in both cases hurting revenue and profits.

|

While CEO Bresch’s family ties may mute the ire of somelawmakers, others are already asking the company about taxpayershaving to foot the bill for these price increases --particularly after Bresch and the company successfully pushedlegislation to encourage use of the EpiPen in schoolsnationwide.

|

Mylan is the latest drugmaker to provoke congressional ire forsteep price hikes. Martin Shkreli and executives from thecompany he used to lead, Turing Pharmaceuticals AG, and executivesfrom Valeant Pharmaceuticals International Inc. were called beforecongressional committees earlier this year to explain why theybought the rights to older drugs that lacked competition and raisedthe prices.

|

Mainstream drug

The Mylan controversy fits a similar pattern. Mylan hasincreased the price of its EpiPen from about $57 a shot when ittook over sales of the product in 2007 to more than $600 for twoauto-injectors. But the company’s EpiPen is a more mainstream drugused to treat life-threatening allergic reactions from bee stings,food allergies or other triggers, which could give the issue alarger constituency.

|

Mylan declined to comment when asked to explain the price hikeor Bresch’s role in promoting legislation. Manchin’s office alsodidn’t respond to requests for comment.

|

Members in both chambers expressed outrage this week.

|

|

“I am deeply concerned by this significant price increase for aproduct that has been on the market for more than three decades,and by Mylan’s failure to publicly explain the recent costincrease, which places a significant burden on parents, schools andother purchasers of the EpiPen,” Senator Mark Warner, a VirginiaDemocrat, said Tuesday in a statement, noting that he is aparent of a child with severe allergies.

|

On Wednesday, the Senate Special Committee on Aging asked Breschto turn over information used by Mylan’s board of directors relatedto the price increases. The panel wrote a letter to Bresch askingher to “provide a briefing to Committee staff on the pricing ofEpiPen at a mutually convenient time no later than two weeks fromtoday.” The letter was signed by the committee’s chairman,Republican Senator Susan Collins of Maine, and its top Democrat,Claire McCaskill of Missouri.

|

Senator Richard Blumenthal, a Connecticut Democrat who hasasked the company to lower its prices, is holding an event onWednesday where he will call for investigations by the SenateJudiciary Committee and the Federal Trade Commission into potentialantitrust violations and deceptive and illegal trade practices.

|

Campaign fodder

The issue of the price increase became presidential campaignfodder after Clinton issued her statement.

|

“Since there is no apparent justification in this case, I amcalling on Mylan to immediately reduce the price of EpiPens,”Clinton said in a statement from her campaign.

|

Mylan’s shares, which have dropped this week as the scrutinyincreased, fell further after Clinton’s comments. The stock wasdown 6.1 percent to $42.86 at 3:25 p.m. in New York, bringing thethree-day losses to more than 11 percent.

|

Congressional anger may be fueled by the company’s tactics inpushing legislation that helped boost the use of EpiPens.

|

|

Mylan spent about $4 million in 2012 and 2013 on lobbying foraccess to EpiPens generally and for legislation, including the 2013School Access to Emergency Epinephrine Act, according to lobbyingdisclosure forms filed with the Office of the Clerk for the Houseof Representatives. Mylan also was the top corporate sponsorof a group called Food Allergy Research & Education that wasthe key lobbyist pushing for the bill encouraging schools to stockepinephrine auto-injectors, of which EpiPen is by far the leadingproduct.

|

Tiptoeing around Bresch

But Bresch’s connections to Capitol Hill already have somelawmakers tiptoeing around the usual Washington blame game.

|

For example, Blumenthal, a member of the Senate JudiciaryCommittee and a co-sponsor of the 2013 schools bill, asked Breschin a letter Monday to explain the “shocking price increases.”

|

However, in an interview Tuesday, he was less eager to talkabout Bresch herself or the prospect that she might soon betestifying to the committee.

|

He initially answered during one telephone call that he wasunaware that she had any direct involvement in the pricing. Then,in a follow-up call, Blumenthal responded when asked again aboutthe possibility of her coming before Congress by saying, “I am justnot going to comment on that.”

|

Bresch, 47, has been CEO of Mylan since 2012 and previously heldother senior posts at the company, including as head of governmentrelations. Last year, she had to defend the company after it movedits corporate address overseas to lower its U.S. taxes in atransaction known as an inversion. Now incorporated in theNetherlands, its principal executive office is in Canonsburg,Pennsylvania.

|

|

Recuse himself

Ross Baker, a political scientist at Rutgers University in NewJersey, said Tuesday that he assumes Bresch’s father, Manchin --who is not on the Judiciary Committee -- would recuse himself “andput a lot of distance between himself and any investigation” intothe matter.

|

“He’d be unwise to rise to the defense of Mylan,”Baker said.

|

Senate Judiciary Chairman Chuck Grassley of Iowa, who is runningfor re-election, also wrote a letter to Mylan saying he was“concerned that the substantial price increase could limit accessto a much-needed medication,” asking for an explanation by Sept. 6,the day the Senate returns from its seven-week summer recess. JillGerber, Grassley’s spokeswoman, said in an e-mail that he wants tohear back from Mylan before considering holding a hearing.

|

School program

Mylan has given away more than 700,000 free EpiPen’s to schoolssince 2012 under a program that allows them to receive four freeauto-injectors, the company said in a statement. Yet schools haveto use their own funds to purchase additional pens. Mylan declinedto comment on the price increases coinciding with legislation toencourage EpiPen use.

|

Senator Amy Klobuchar, a Minnesota Democrat, asked the FederalTrade Commission on Monday to look into whether Mylan had doneanything to deny competitors access to the market in order to keepraising prices. She pointed to a competitor product, Adrenaclick,that she said is less expensive but has only minimal sales.Klobuchar was also a co-sponsor of the schools bill.

|

In the House on Tuesday, majority and minority staff members ofthe Oversight and Government Reform Committee held a meeting afterreceiving a letter from Representative Grace Meng, a New YorkDemocrat, requesting the panel hold a hearing.

|

The majority staff scheduled a call with the company, thoughDemocrats on the committee said they were waiting to hear back onwhether a hearing will be scheduled.

|

No hearing, no comment

A spokeswoman for committee Chairman Jason Chaffetz of Utah,said that as of Tuesday afternoon no hearing was scheduled. “And nocomment beyond that,” said the spokeswoman, M.J. Henshaw.

|

The top Democrat on the Oversight Committee, Elijah Cummings ofMaryland, said Tuesday that he wants a hearing when lawmakersreturn from their summer break to Washington in September.

|

“The recent price increase for EpiPens places a financial burdenon those who desperately need this drug to prevent life threateningallergic reactions, which is why we have expressed our desire foran investigation of this issue and for the Committee to hold ahearing in September,” Cummings said Tuesday in astatement.

|

Copyright 2018 Bloomberg. All rightsreserved. This material may not be published, broadcast, rewritten,or redistributed.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.